hoe 33342 and Pituitary Neoplasms

hoe 33342 has been researched along with Pituitary Neoplasms in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Griffiths, JR; Howe, FA; Robinson, SP; Ryan, AJ; Waterton, JC	1

Other Studies

1 other study(ies) available for hoe 33342 and Pituitary Neoplasms

Article	Year
Susceptibility contrast magnetic resonance imaging determination of fractional tumor blood volume: a noninvasive imaging biomarker of response to the vascular disrupting agent ZD6126. International journal of radiation oncology, biology, physics, 2007, Nov-01, Volume: 69, Issue:3 Topics: Animals; Benzimidazoles; Blood Volume; Contrast Media; Dextrans; Female; Ferrosoferric Oxide; Fluorescent Dyes; Iron; Magnetic Resonance Imaging; Magnetite Nanoparticles; Organophosphorus Compounds; Oxides; Pituitary Neoplasms; Prolactinoma; Rats	2007

Article

Year

Susceptibility contrast magnetic resonance imaging determination of fractional tumor blood volume: a noninvasive imaging biomarker of response to the vascular disrupting agent ZD6126.

International journal of radiation oncology, biology, physics, 2007, Nov-01, Volume: 69, Issue:3

Topics: Animals; Benzimidazoles; Blood Volume; Contrast Media; Dextrans; Female; Ferrosoferric Oxide; Fluorescent Dyes; Iron; Magnetic Resonance Imaging; Magnetite Nanoparticles; Organophosphorus Compounds; Oxides; Pituitary Neoplasms; Prolactinoma; Rats

2007